SELENOI

Across TCGA pan-cancer cohorts, SELENOI RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SELENOI’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SELENOI RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SELENOI is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

BLCA, LUAD, and HNSC are the cancer types where SELENOI tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SELENOI RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+2.081	<.001	12	view →
LUAD	Male	II,III,IV	+1.605	<.001	11	view →
HNSC	Male	All	+1.054	<.001	11	view →
STAD	All	II,III,IV	+1.107	<.001	10	view →
LUSC	Male	II,III,IV	+1.883	<.001	9	view →
COAD	Male	All	+0.791	<.001	8	view →
UCEC	All	III,IV	+1.655	<.001	6	view →
BRCA	All	II,III,IV	+1.159	<.001	6	view →
LIHC	Male	All	+0.618	.001	6	view →
THCA	All	All	−0.368	<.001	6	view →
KIRC	Male	III,IV	−0.349	.017	4	view →
CHOL	All	All	+0.754	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SELENOI–BLCA

Open the BLCA breakdown →